Lack of school psychologists leaves parents paying thousands for private assessments

Only 6 of 45 anglophone school psychologist positions are filled in New Brunswick (≈1 psychologist per 13,000 students) versus the Canadian Psychological Association’s recommended minimum — a shortage prompting families to pay ~$3,000 for private autism assessments. About 65% of provincial psychologists work in private practice, UNB’s PhD program has just six seats (recent incremental funding ended), and the province is pursuing short-term training partnerships and retention strategies. Policy moves in neighbouring Nova Scotia to provincially fund certain therapy services are cited as a potential model to reduce waitlists and out-of-pocket costs.

Analysis

The market opportunity is less about a single policy fix and more about a multi-year supply-demand mismatch: training and certifying clinical psychologists is a slow, resource-intensive process with 3–6+ year lag times, while demand from schools and families responds immediately to visible gaps. That gap creates durable pricing power for private assessment providers and platformized tele-mental-health triage, but also invites automation and credential-substitution (psychometrists, master's-level clinicians) which will compress per-case revenue over time.

Provincial governments facing visible constituency pain are likely to pursue quick policy remedies (coverage expansions, short-term contract hires, training subsidies) ahead of structural solutions; those actions will reallocate budget dollars to benefit-management firms, telehealth networks and staffing vendors in the near term while leaving structural under-supply intact for years. Expect two second-order flows: (1) private providers scale via partnerships with public payers, raising M&A and revenue multiple re-ratings in 6–24 months, and (2) assessment product vendors and software that reduce clinician time per case will capture margin upside as payers demand efficiency.

Politically, mental-health access is a low-cost, high-salience issue that can accelerate provincial rollouts of publicly-funded services; near-term catalysts include provincial budgets and union negotiations. The contrarian risk is rapid adoption of tele-assessment and psychometric automation that materially reduces the volume of high-margin in-person assessments within 12–36 months, turning a near-term winner set into a structural loser unless they adapt to scale and SaaS delivery.

Key Decisions for Investors

• Long TDOC (Teladoc) — 6–18 month horizon. Rationale: increased provincial/public coverage and employer benefits expansion should lift tele-mental-health utilization and B2B contracting. Trade structure: buy Jan +12-month 2027 50-65 call spread (debit) to cap premium while keeping upside if utilization accelerates. Risk/reward: limited downside (~max premium) vs 2–3x upside if revenue growth re-accelerates on payer contracts.
• Long AMN (AMN Healthcare) — 3–12 month horizon. Rationale: staffing demand for allied mental-health professionals and short-term contract placements will spike before supply-side training responds. Position: buy shares with a 6% stop; take profits as quarterly staffing fill rates climb. Risk: temporary nature of contracts and margin pressure if rates capped by public payers.
• Long UNH (UnitedHealth/Optum) — 12–24 month horizon. Rationale: benefit managers capture large share of new publicly-funded outpatient mental-health flows and can scale networked providers; look for incremental margins from higher utilization. Position: buy UNH, hedge with a 25–35% protective put for 12 months if near-term political backlash or regulation compresses pricing. Reward: stable cash flow uplift; risk: regulatory scrutiny on pricing.
• Tactical pair: long telehealth staffing/software / short boutique in-person assessment clinics (no single-ticker pair) — 6–24 months. Rationale: favor scalable, platform-driven providers and SaaS vendors over fragmented, high-cost local clinics that will be price-competitive once public coverage expands. Implementation: buy platform equities (TDOC/AMN) and reduce exposure to small-cap/private clinic names via selective short or avoid direct investment in boutique chains. Risk: automation/adoption may take longer than expected, delaying gains.